"Information is one of our greatest resources. PharmaTex Research, LLC conducts clinical studies and drug research to collect vital data about health, medicine and the human body. Our clinical research facility invites participants to help us in our research. You can aid the cause by volunteering for a clinical study today. Our multi-specialty clinical research facility is dedicated to collecting accurate and vital data for pharmaceutical research. Our goal is to provide treatment alternatives to patients in need while furthering pharmacological and device research, which will ultimately have a positive impact on our community at large."

During the past decade, PharmaTex Research, LLC conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 6 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 6 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PharmaTex Research, LLC" #1 sponsor was "Pfizer" with 3 trials, followed by "Regeneron Pharmaceuticals" with 3 trials sponsored, "Bayer" with 2 trials sponsored, "American Regent, Inc." with 1 trials sponsored and "AtheroGenics" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PharmaTex Research, LLC" #1 collaborator was "Duke Clinical Research Institute" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "PharmaTex Research, LLC" are "COVID-19" (5 trials), "Acute Myocardial Infarction" (1 trials), "Atherosclerosis" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "PharmaTex Research, LLC" in a lesser frequency.

Most popular intervention types in "PharmaTex Research, LLC" are "Drug" (17 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "PF-07321332" (3 trials), "Ritonavir" (3 trials), "AGI-1067" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "PharmaTex Research, LLC" are 18 trials for "All" genders.

Currently, there are NaN active trials in "PharmaTex Research, LLC". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in PharmaTex Research, LLC, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in PharmaTex Research, LLC, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".